Onconetix, Inc. Files 8-K

TL;DR

Onconetix (ONCO) filed an 8-K on Jan 22 for an event on Jan 15.

AI Summary

Onconetix, Inc. filed an 8-K on January 22, 2025, reporting an event that occurred on January 15, 2025. The filing is categorized under 'Other Events' and includes financial statements and exhibits. The company, formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines Inc., is incorporated in Delaware and headquartered in Cincinnati, Ohio.

Why It Matters

This 8-K filing indicates a significant corporate event or update for Onconetix, Inc., requiring disclosure to investors and the public.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for 'Other Events' and does not immediately indicate significant financial distress or operational changes.

Key Players & Entities

• Onconetix, Inc. (company) — Registrant
• January 15, 2025 (date) — Earliest event date
• January 22, 2025 (date) — Filing date
• Blue Water Biotech, Inc. (company) — Former company name
• Blue Water Vaccines Inc. (company) — Former company name
• 201 E. Fifth Street, Suite 1900, Cincinnati, Ohio 45202 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.00001 — ch Registered Common Stock, par value $0.00001 per share ONCO The Nasdaq Stock Mar
• $150,000 — agreed to pay to IQVIA an aggregate of $150,000 in exchange for a mutual release of all

Filing Documents

• ea0228132-8k_onconetix.htm (8-K) — 30KB
• ea022813201ex99-1_onconetix.htm (EX-99.1) — 31KB
• ea022813201ex99-2_onconetix.htm (EX-99.2) — 1KB
• ex99-2.jpg (GRAPHIC) — 556KB
• 0001213900-25-005521.txt ( ) — 1009KB
• onco-20250115.xsd (EX-101.SCH) — 3KB
• onco-20250115_lab.xml (EX-101.LAB) — 33KB
• onco-20250115_pre.xml (EX-101.PRE) — 22KB
• ea0228132-8k_onconetix_htm.xml (XML) — 4KB

01. Other Events

Item 8.01. Other Events IQVIA Settlement As previously disclosed in Current Reports on Form 8-K filed on July 21, 2023 and October 18, 2023, Onconetix, Inc. (the "Company") entered into a Licensing and Services Master Agreement ("Master Services Agreement") and a related statement of work with IQVIA, Inc. ("IQVIA") on July 21, 2023, and a second statement of work on July 29, 2023, which were terminated on October 12, 2023. On January 15, 2025, the Company and IQVIA entered into a Settlement Agreement (the "Settlement Agreement") concerning potential termination payments under the Master Services Agreement and statements of work. Pursuant to the Settlement Agreement, the Company agreed to pay to IQVIA an aggregate of $150,000 in exchange for a mutual release of all claims in connection with the Master Services Agreement. As a result of the Settlement Agreement, the Company will record an adjustment of approximately $(0.9) million in accounts payable. The foregoing description of the Settlement Agreement is not complete and is subject to and qualified in its entirety by reference to the full text of such document, which is filed as Exhibit 99.1 hereto and incorporated herein by reference. Proclarix Publication On January 22, 2025, Proteomedix AG, the Company's wholly-owned subsidiary, posted on Linkedin.com on a recent study concerning potential clinical benefits of Proclarix in detecting and stratifying the risk of clinically significant prostate cancer (csPCa). A copy of the post is filed as Exhibit 99.2 hereto and is incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibits 99.1 Settlement Agreement, dated January 15, 2025 99.2 Linkedin Posting, dated January 22, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCONETIX, INC. Date: January 22, 2025 By: /s/ Karina M. Fedasz Name: Karina M. Fedasz Title: Interim Chief Financial Officer 2